Preferred Primary Care Physicians Inc

1. Eli Lilly and Company $8,548,559 260 payments
2. Pfizer Inc. $1,540,110 334 payments
3. Esperion Therapeutics, Inc. $143,102 239 payments
4. Adaptive Biotechnologies Corporation $142,582 4 payments
5. Moderna TX, Inc. $140,020 26 payments
6. GlaxoSmithKline, LLC. $125,541 54 payments
7. Kowa Research Institute, Inc. $114,885 34 payments
8. Novavax Inc $55,620 30 payments
9. Teva Pharmaceuticals USA, Inc. $38,180 22 payments
10. Novartis Pharmaceuticals Corporation $35,002 2 payments

1. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial $796,271 9 payments
2. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $678,894 10 payments
3. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $546,367 49 payments
4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $434,735 4 payments
5. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $421,170 53 payments
6. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 Administered Weekly Using A Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naive Adults With Type 2 Diabetes $382,443 2 payments
7. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $356,127 4 payments
8. Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity Or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-2) $313,594 4 payments
9. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $310,129 5 payments
10. A Phase 2, Parallel, Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Insulin Naive Patients With Type 2 Diabetes Mellitus $309,315 5 payments

1. Other $142,582 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.